Abstract
Background and Aims Hepatitis B virus (HBV) generates a double-stranded linear DNA (dslDNA) byproduct during replication. This dslDNA can undergo intermolecular and intramolecular nonhomologous end-joining (NHEJ) recombination, resulting in viral integration and dslDNA derived covalently closed circular DNAs (dsl-cccDNAs), respectively. The insertions and deletions (INDELs) at the end-joining site around the direct repeat (DR) 1 motif have been used to differentiate dsl-cccDNA from the authentic cccDNA. The frequency and characteristics of dsl-cccDNA in chronic hepatitis B (CHB) patients remain unclear.
Methods HBV-targeted next-generation sequencing (NGS) was used to identify 32 dsl-cccDNA positive candidates, 22 HBeAg(+) and 10 HBeAg(-), from 56 liver biopsies of antiviral treatment-naive CHB patients for dsl-cccDNA confirmation and characterization by cccDNA-PCR NGS. INDELs within the DR2-1 region (nt 1600–1840) of the cccDNA were analyzed.
Results Various clonally expanded, heterogenous ∼22-nt deletions in the X-gene were detected in all 32 samples, which are likely quasi-species from the authentic cccDNA. We, therefore, defined dsl-cccDNA only by the presence of INDELs clustered at the DR1 surrounding region (nt 1800–1840). The percentage of dsl-cccDNA in total cccDNA was higher among HBeAg(+) compared to HBeAg(-) samples [11.32 (3.24–26.94)% vs. 7.72 (2.16–28.23)%, p=0.01]. The diversity of dsl-cccDNA species correlated with cccDNA levels (log-transformed; r=0.82, p<0.001), HBeAg(+) CHB (p<0.001), and serum HBV DNA (p<0.001).
Conclusions dsl-cccDNA is more prevalent and heterogenous among the HBeAg(+) CHB subjects, which is likely due to the active viral cccDNA transcription and reverse transcription at the HBeAg(+) phase. The existence of replication-defective dsl-cccDNA may facilitate immune evasion and HBV integration, and complicate HBV pathogenesis. The potential impact of dsl-cccDNA in HBV therapeutic response deserves further assessment.
Competing Interest Statement
SL, ZW, and YS: Shareholder of JBS Science Inc. SL, FS, and ZW are employees of JBS Science, Inc at the time of the study. All other authors declare no competing interests.
Funding Statement
This study is supported by grants from the National Institutes of Health (R56AI179574 to DL, YS, and HG; R01AI110762, R01AI150255, R21AI179929 to HG; U01DK082919-010 to DL; U01CA275648 to YS; R43AI167169 to SL); R01AI155140 to RTC.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The patient tissue specimens were collected through the HBRN Adult Cohort Study (NCT01263587), which includes 21 clinical sites across the US and Canada. The HBRN study protocols were approved by the institutional review boards (Research Ethics Board in the case of the Toronto site) of each participating institution, and each participant provided written, informed consent. A list of the 21 clinical sites is provided below: Los Angeles, California, United States, 90048 Cedars Sinai Medical Center Los Angeles, California, United States, 90095 University of California Los Angeles San Francisco, California, United States, 94115 California Pacic Medical Center San Francisco, California, United States, 94143 University of California San Francisco Honolulu, Hawaii, United States, 96813 The Queen's Medial Center Bethesda, Maryland, United States, 20892 NIH Clinical Center Boston, Massachusetts, United States, 02114 Massachusetts General Hospital Boston, Massachusetts, United States, 02215 Beth Israel Deaconess Medical Center Ann Arbor, Michigan, United States, 48109 University of Michigan Health System Minneapolis, Minnesota, United States, 55455 University of Minnesota Rochester, Minnesota, United States, 55905 Mayo Clinic Saint Louis, Missouri, United States, 63104 Saint Louis University Saint Louis, Missouri, United States, 63108 Washington University Chapel Hill, North Carolina, United States, 27599 University of North Carolina Durham, North Carolina, United States, 27710 Duke University Medical Center Dallas, Texas, United States, 75246 Baylor University Medical Center Dallas, Texas, United States, 75390 University of Texas Southwestern Richmond, Virginia, United States, 23298 Virginia Commonwealth University Medical Center Seattle, Washington, United States, 98101 Virginia Mason Medical Center Seattle, Washington, United States, 98104 Harborview Medical Center Ontario Locations Toronto, Ontario, Canada Toronto Western Hospital Liver Centre
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Conflict of interest: SL, ZW, and YS: Shareholder of JBS Science Inc. SL, FS, and ZW are employees of JBS Science, Inc at the time of the study. All other authors declare no competing interests.
Financial support: This study is supported by grants from the National Institutes of Health (R56AI179574 to DL, YS, and HG; R01AI110762, R01AI150255, R21AI179929 to HG; U01DK082919-010 to DL; U01CA275648 to YS; R43AI167169 to SL); R01AI155140 to RTC.
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.